Terconazole for Vulvovaginal Candidiasis
Terconazole is an effective prescription topical azole for treating uncomplicated vulvovaginal candidiasis, available as 0.4% cream (7-day regimen), 0.8% cream (3-day regimen), or 80 mg suppository (3-day regimen), all administered intravaginally once daily at bedtime. 1, 2
Dosing Regimens
The FDA-approved dosing options are 2:
- Terconazole 0.4% cream: 5 g (20 mg terconazole) intravaginally once daily at bedtime for 7 consecutive days
- Terconazole 0.8% cream: 5 g (40 mg terconazole) intravaginally once daily at bedtime for 3 consecutive days
- Terconazole 80 mg suppository: One suppository intravaginally once daily for 3 consecutive days
All regimens are included in the 2021 CDC STI treatment guidelines as recommended prescription options for uncomplicated VVC 1.
Administration Instructions
- Apply at bedtime for optimal retention
- Menstruation does not affect therapeutic efficacy 2
- Before prescribing a repeat course, reconfirm diagnosis with microscopy and/or culture and rule out other pathogens 2
Clinical Efficacy
Terconazole demonstrates high cure rates comparable to other azoles:
- Short-term (7-14 days): Clinical cure rates of 81-96% and mycological cure rates of 77-91% 3, 4
- Long-term (30-35 days): Clinical cure rates of 60% and mycological cure rates of 62% 3
- The 0.4% cream formulation provides significantly fewer adverse genital reactions compared to miconazole 2% cream while maintaining similar efficacy 5
Safety Profile and Adverse Effects
Terconazole is generally well-tolerated with primarily local side effects 2:
Common adverse effects:
- Headache (21-26% vs. 16-17% with placebo)
- Vulvovaginal burning (5.2%), itching (2.3%), or irritation (3.1%) - notably less frequent than placebo
- Dysmenorrhea (6% vs. 2% with placebo)
- Body pain (2.1%)
Rare but notable systemic reactions:
- One case report documented chills, fatigue, chest distress, and elevated inflammatory markers (WBC, neutrophils, CRP, PCT) that resolved with drug removal and IV fluids without antibiotics 6
- Fever (1-1.7%) and chills (0.4%) have been reported 2
The therapy-related dropout rate is low (1.9-2.0%), with vulvovaginal itching being the most common reason for discontinuation (0.6-0.7%) 2.
Contraindications and Precautions
While the FDA label does not list absolute contraindications, avoid terconazole during pregnancy as recommended by expert consensus 7. The drug label does not specifically address pregnancy, but expert guidelines recommend topical azoles other than terconazole as preferred agents during pregnancy.
Special Populations and Clinical Contexts
Recurrent VVC (RVVC): For maintenance therapy after initial treatment, terconazole can be used intermittently at 1-3 times weekly, with twice-weekly dosing being the most commonly utilized regimen 7.
Severe VVC: A 6-day course of terconazole 80 mg suppositories showed comparable efficacy to two doses of oral fluconazole 150 mg, with local irritation as the primary adverse effect versus systemic effects with fluconazole 3.
Clinical Pitfalls to Avoid
- Do not rely solely on clinical diagnosis or microscopy, which have poor sensitivity (<60%). Culture or PCR testing provides superior diagnostic accuracy (sensitivity >90%) 1
- Avoid treating without objective confirmation, as less than half of patients treated for VVC actually have the infection 1
- Do not prescribe repeat courses without reconfirming diagnosis and ruling out other pathogens 2
- Be aware that while terconazole is highly effective, single-dose oral fluconazole has marginally higher early mycological cure rates in network meta-analyses 8